Literature DB >> 23714173

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

G Jackson1, A Nehra, M Miner, K L Billups, A L Burnett, J Buvat, C C Carson, G Cunningham, I Goldstein, A T Guay, G Hackett, R A Kloner, J B Kostis, P Montorsi, M Ramsey, R Rosen, R Sadovsky, A D Seftel, R Shabsigh, C Vlachopoulos, F C W Wu.   

Abstract

Erectile dysfunction (ED) and cardiovascular disease (CVD) share risk factors and frequently coexist, with endothelial dysfunction believed to be the pathophysiologic link. ED is common, affecting more than 70% of men with known CVD. In addition, clinical studies have demonstrated that ED in men with no known CVD often precedes a CVD event by 2-5 years. ED severity has been correlated with increasing plaque burden in patients with coronary artery disease. ED is an independent marker of increased CVD risk including all-cause and especially CVD mortality, particularly in men aged 30-60 years. Thus, ED identifies a window of opportunity for CVD risk mitigation. We recommend that a thorough history, physical exam (including visceral adiposity), assessment of ED severity and duration and evaluation including fasting plasma glucose, lipids, resting electrocardiogram, family history, lifestyle factors, serum creatinine (estimated glomerular filtration rate) and albumin:creatinine ratio, and determination of the presence or absence of the metabolic syndrome be performed to characterise cardiovascular risk in all men with ED. Assessment of testosterone levels should also be considered and biomarkers may help to further quantify risk, even though their roles in development of CVD have not been firmly established. Finally, we recommend that a question about ED be included in assessment of CVD risk in all men and be added to CVD risk assessment guidelines.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23714173     DOI: 10.1111/ijcp.12200

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  9 in total

1.  2015 CUA Practice guidelines for erectile dysfunction.

Authors:  Anthony J Bella; Jay C Lee; Serge Carrier; Francois Bénard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

2.  The implications of low testosterone on mortality in men.

Authors:  Molly M Shores
Journal:  Curr Sex Health Rep       Date:  2014-12-01

3.  Subclinical Vascular Disease and Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA).

Authors:  David I Feldman; Miguel Cainzos-Achirica; Kevin L Billups; Andrew P DeFilippis; Kanchan Chitaley; Philip Greenland; James H Stein; Matthew J Budoff; Zeina Dardari; Martin Miner; Roger S Blumenthal; Khurram Nasir; Michael J Blaha
Journal:  Clin Cardiol       Date:  2016-05-03       Impact factor: 2.882

Review 4.  The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review.

Authors:  Omer A Raheem; Jeannie J Su; Joel R Wilson; Tung-Chin Hsieh
Journal:  Am J Mens Health       Date:  2016-02-04

5.  Sexual health of male cardiac patients - present status and expectations of patients with coronary heart disease.

Authors:  Dariusz Kałka; Łukasz Karpiński; Jana Gebala; Lesław Rusiecki; Anna Biełous-Wilk; Ewa S Krauz; Magdalena Piłot; Krzysztof Womperski; Małgorzata Rusiecka; Witold Pilecki
Journal:  Arch Med Sci       Date:  2017-01-23       Impact factor: 3.318

6.  Relationship between the risk factors of cardiovascular disease by testing biochemical markers and young men with erectile dysfunction: a case-control study.

Authors:  Wen-Jing Ma; Mao Qin; Tian-Wei Cui; Xiu-Ping Zhang; Zheng-Hao Ke; Zhen-Kun Pan; Yun-Xiao Gao; Bao-Xing Liu
Journal:  Transl Androl Urol       Date:  2021-02

7.  Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.

Authors:  Daniel P Andersson; Ylva Trolle Lagerros; Alessandra Grotta; Rino Bellocco; Mikael Lehtihet; Martin J Holzmann
Journal:  Heart       Date:  2017-03-09       Impact factor: 5.994

Review 8.  Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?

Authors:  Geoffrey Hackett
Journal:  World J Mens Health       Date:  2020-03-26       Impact factor: 5.400

9.  Survival of Patients on Hemodialysis with Erectile Dysfunction.

Authors:  Radojica V Stolic; Zoran Bukumiric; Branislav Belic; Bozidar Odalovic; Goran Relic; Sasa Sovtic; Maja Sipic; Vekoslav Mitrovic; Biljana Krdzic
Journal:  Medicina (Kaunas)       Date:  2020-09-24       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.